Marpai

Marpai, Inc. (MRAI) announced its Q3 2025 results, demonstrating a continued turnaround driven by cost discipline and operational efficiency. Operating expenses decreased by 24%, and the operating loss narrowed by 9%. The company’s sales pipeline is strong, with double-digit new client contracts signed. MarpaiRx, the company’s integrated PBM offering, is a key differentiator. Marpai completed a PIPE, securing $3.9 million. Marpai anticipates achieving profitability in Q1 2026, fueled by a robust deal pipeline.